Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ESPERION THERAPEUTICS, INC.

(ESPR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
7.78(c) 8.68(c) 8.73(c) 8.04(c) 8.97(c) Last
1 295 418 1 133 873 2 605 401 2 517 589 2 114 547 Volume
+1.17% +11.57% +0.58% -7.90% +11.57% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 78,1 M - -
Net income 2021 -283 M - -
Net Debt 2021 338 M - -
P/E ratio 2021 -0,84x
Yield 2021 -
Sales 2022 113 M - -
Net income 2022 -154 M - -
Net Debt 2022 336 M - -
P/E ratio 2022 -2,03x
Yield 2022 -
Capitalization 261 M 261 M -
EV / Sales 2021 7,66x
EV / Sales 2022 5,26x
Nbr of Employees -
Free-Float 91,9%
More Financials
Company
Esperion Therapeutics, Inc. is a lipid management company. The Company is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with... 
Sector
Pharmaceuticals
Calendar
02/22Earnings Release
More about the company
Ratings of Esperion Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ESPERION THERAPEUTICS, INC.
12/02Esperion Announces Pricing of $225 Million Public Offering
AQ
12/02Esperion Therapeutics Plans Public Offering of Common Stock, Warrants -- Stock Drops Af..
MT
12/02Esperion Announces Proposed Public Offering
GL
11/24Esperion Therapeutics Shares Tumble 20% in Afternoon Trading; Volume 5x Higher at 5.6 M..
MT
11/12Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL« (b..
GL
11/12Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL« (b..
GL
11/08Landos Biopharma Appoints Tim Mayleben Interim Chief Executive
MT
11/02ESPERION THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
11/02Esperion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
11/02ESPERION THERAPEUTICS : Q3 Earnings Snapshot
AQ
11/02Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update - For..
PU
11/02Earnings Flash (ESPR) ESPERION THERAPEUTICS Reports Q3 Revenue $14.4M, vs. Street Est o..
MT
11/02Earnings Flash (ESPR) ESPERION THERAPEUTICS Reports Q3 Loss $-2.62, vs. Street Est of $..
MT
11/02Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update
AQ
11/01Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors - For..
PU
More news
News in other languages on ESPERION THERAPEUTICS, INC.
12/02Esperion Therapeutics propose une offre publique d'actions ordinaires et de bons de sou..
11/08Landos Biopharma nomme Tim Mayleben chef de la direction par intérim
11/02Earnings Flash (ESPR) ESPERION THERAPEUTICS annonce un chiffre d'affaires de 14,4 milli..
08/03Earnings Flash (ESPR) ESPERION THERAPEUTICS affiche un chiffre d'affaires de 40,7 milli..
06/28Esperion Therapeutics nomme un directeur médical en chef
More news
Analyst Recommendations on ESPERION THERAPEUTICS, INC.
More recommendations
Chart ESPERION THERAPEUTICS, INC.
Duration : Period :
Esperion Therapeutics, Inc. Technical Analysis Chart | ESPR | US29664W1053 | MarketScreener
Technical analysis trends ESPERION THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 8,97 $
Average target price 15,18 $
Spread / Average Target 69,3%
EPS Revisions
Managers and Directors
Sheldon L. Koenig President, Chief Executive Officer & Director
Richard B. Bartram Chief Financial Officer
William J. Sasiela Senior Vice President-Clinical Development
Ken Fiorelli Chief Technical Operations Officer
JoAnne Micale Foody Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ESPERION THERAPEUTICS, INC.-65.50%261
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
PFIZER, INC.48.55%306 912
NOVO NORDISK A/S66.91%247 444
ELI LILLY AND COMPANY47.55%225 859